FDA accepted Milestone Pharmaceuticals Inc.’s response to the Complete Response Letter for CARDAMYST™ Nasal Spray, setting a new target date of December 13, 2025. The company raised up to $170 million in a public offering and extended a $75 million royalty payment agreement. Financial results show cash, cash equivalents, and short-term investments of $43.4 million as of June 30, 2025. Milestone completed a public equity offering in July 2025, raising $48.7 million in net proceeds and intends to use the funds for development and commercial launch of CARDAMYST. The company also extended a $75 million royalty payment agreement with RTW to fund continued development and commercial launch of CARDAMYST. Milestone Pharmaceuticals Inc. reported financial results for the second quarter of 2025, showing a net loss of $13.0 million for the quarter and $33.7 million for the first six months of the year. Research and development expenses increased to $3.7 million for the second quarter of 2025. General and administrative expenses decreased to $3.8 million for the second quarter of 2025. Commercial expenses increased to $5.1 million for the second quarter of 2025. The company’s net loss was $13.0 million for the second quarter of 2025 and $33.7 million for the first six months of the year. Milestone Pharmaceuticals Inc. is a biopharmaceutical company developing cardiovascular solutions and commercializing innovative treatments for heart conditions. Their lead product, etripamil, is a calcium channel blocker nasal spray for patients with PSVT and AFib-RVR. The company’s focus is on improving patient experience and providing new treatment options for patient self-management. Milestone Pharmaceuticals Inc. reported financial results for the second quarter of 2025, showing a net loss of $13.0 million for the quarter and $33.7 million for the first six months of the year. Research and development expenses increased to $3.7 million for the second quarter of 2025. General and administrative expenses decreased to $3.8 million for the second quarter of 2025. Commercial expenses increased to $5.1 million for the second quarter of 2025. The company’s net loss was $13.0 million for the second quarter of 2025 and $33.7 million for the first six months of the year.

Read more at GlobeNewswire: Milestone Pharmaceuticals Reports Second Quarter 2025